These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 34774129)

  • 1. Structural basis of Apt48 inhibition of the BCL6 BTB domain.
    Zacharchenko T; Kalverda AP; Wright SC
    Structure; 2022 Mar; 30(3):396-407.e3. PubMed ID: 34774129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Backbone resonance assignment of the BCL6-BTB/POZ domain.
    Lin LY; Evans SE; Fairall L; Schwabe JWR; Wagner SD; Muskett FW
    Biomol NMR Assign; 2018 Apr; 12(1):47-50. PubMed ID: 28929458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure of a BCOR corepressor peptide in complex with the BCL6 BTB domain dimer.
    Ghetu AF; Corcoran CM; Cerchietti L; Bardwell VJ; Melnick A; Privé GG
    Mol Cell; 2008 Feb; 29(3):384-91. PubMed ID: 18280243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress toward B-Cell Lymphoma 6 BTB Domain Inhibitors for the Treatment of Diffuse Large B-Cell Lymphoma and Beyond.
    Ai Y; Hwang L; MacKerell AD; Melnick A; Xue F
    J Med Chem; 2021 Apr; 64(8):4333-4358. PubMed ID: 33844535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of Thiourea-Based Inhibitors of the B-Cell Lymphoma 6 BTB Domain via NMR-Based Fragment Screening and Computer-Aided Drug Design.
    Cheng H; Linhares BM; Yu W; Cardenas MG; Ai Y; Jiang W; Winkler A; Cohen S; Melnick A; MacKerell A; Cierpicki T; Xue F
    J Med Chem; 2018 Sep; 61(17):7573-7588. PubMed ID: 29969259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein.
    Dhordain P; Albagli O; Lin RJ; Ansieau S; Quief S; Leutz A; Kerckaert JP; Evans RM; Leprince D
    Proc Natl Acad Sci U S A; 1997 Sep; 94(20):10762-7. PubMed ID: 9380707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A peptide aptamer to antagonize BCL-6 function.
    Chattopadhyay A; Tate SA; Beswick RW; Wagner SD; Ko Ferrigno P
    Oncogene; 2006 Apr; 25(15):2223-33. PubMed ID: 16331266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The LAZ3/BCL6 oncogene encodes a sequence-specific transcriptional inhibitor: a novel function for the BTB/POZ domain as an autonomous repressing domain.
    Deweindt C; Albagli O; Bernardin F; Dhordain P; Quief S; Lantoine D; Kerckaert JP; Leprince D
    Cell Growth Differ; 1995 Dec; 6(12):1495-503. PubMed ID: 9019154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GSK137, a potent small-molecule BCL6 inhibitor with in vivo activity, suppresses antibody responses in mice.
    Pearce AC; Bamford MJ; Barber R; Bridges A; Convery MA; Demetriou C; Evans S; Gobbetti T; Hirst DJ; Holmes DS; Hutchinson JP; Jayne S; Lezina L; McCabe MT; Messenger C; Morley J; Musso MC; Scott-Stevens P; Manso AS; Schofield J; Slocombe T; Somers D; Walker AL; Wyce A; Zhang XP; Wagner SD
    J Biol Chem; 2021 Aug; 297(2):100928. PubMed ID: 34274316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells.
    Polo JM; Dell'Oso T; Ranuncolo SM; Cerchietti L; Beck D; Da Silva GF; Prive GG; Licht JD; Melnick A
    Nat Med; 2004 Dec; 10(12):1329-35. PubMed ID: 15531890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain.
    Ahmad KF; Melnick A; Lax S; Bouchard D; Liu J; Kiang CL; Mayer S; Takahashi S; Licht JD; Privé GG
    Mol Cell; 2003 Dec; 12(6):1551-64. PubMed ID: 14690607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular dynamics analysis of the interaction between the human BCL6 BTB domain and its SMRT, NcoR and BCOR corepressors: the quest for a consensus dynamic pharmacophore.
    Granadino-Roldán JM; Obiol-Pardo C; Pinto M; Garzón A; Rubio-Martínez J
    J Mol Graph Model; 2014 May; 50():142-51. PubMed ID: 24793055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ansamycin antibiotic, rifamycin SV, inhibits BCL6 transcriptional repression and forms a complex with the BCL6-BTB/POZ domain.
    Evans SE; Goult BT; Fairall L; Jamieson AG; Ko Ferrigno P; Ford R; Schwabe JW; Wagner SD
    PLoS One; 2014; 9(3):e90889. PubMed ID: 24595451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutting edge: T follicular helper cell differentiation is defective in the absence of Bcl6 BTB repressor domain function.
    Nance JP; Bélanger S; Johnston RJ; Takemori T; Crotty S
    J Immunol; 2015 Jun; 194(12):5599-603. PubMed ID: 25957170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms.
    Parekh S; Polo JM; Shaknovich R; Juszczynski P; Lev P; Ranuncolo SM; Yin Y; Klein U; Cattoretti G; Dalla Favera R; Shipp MA; Melnick A
    Blood; 2007 Sep; 110(6):2067-74. PubMed ID: 17545502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of an Irreversible and Cell-Active BCL6 Inhibitor Selectively Targeting Cys53 Located at the Protein-Protein Interaction Interface.
    Sameshima T; Yamamoto T; Sano O; Sogabe S; Igaki S; Sakamoto K; Ida K; Gotou M; Imaeda Y; Sakamoto J; Miyahisa I
    Biochemistry; 2018 Feb; 57(8):1369-1379. PubMed ID: 29293322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The NCoR Co-repressor Interacts with the Kaiso Transcription Factor through a Mechanism Different from That of BCL6 Interaction.
    Balagurov KI; Georgiev PG; Bonchuk AN
    Dokl Biochem Biophys; 2022 Dec; 507(1):326-329. PubMed ID: 36786995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6.
    Kerres N; Steurer S; Schlager S; Bader G; Berger H; Caligiuri M; Dank C; Engen JR; Ettmayer P; Fischerauer B; Flotzinger G; Gerlach D; Gerstberger T; Gmaschitz T; Greb P; Han B; Heyes E; Iacob RE; Kessler D; Kölle H; Lamarre L; Lancia DR; Lucas S; Mayer M; Mayr K; Mischerikow N; Mück K; Peinsipp C; Petermann O; Reiser U; Rudolph D; Rumpel K; Salomon C; Scharn D; Schnitzer R; Schrenk A; Schweifer N; Thompson D; Traxler E; Varecka R; Voss T; Weiss-Puxbaum A; Winkler S; Zheng X; Zoephel A; Kraut N; McConnell D; Pearson M; Koegl M
    Cell Rep; 2017 Sep; 20(12):2860-2875. PubMed ID: 28930682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BAZF, a novel Bcl6 homolog, functions as a transcriptional repressor.
    Okabe S; Fukuda T; Ishibashi K; Kojima S; Okada S; Hatano M; Ebara M; Saisho H; Tokuhisa T
    Mol Cell Biol; 1998 Jul; 18(7):4235-44. PubMed ID: 9632807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BTB/POZ zinc finger protein ZBTB16 inhibits breast cancer proliferation and metastasis through upregulating ZBTB28 and antagonizing BCL6/ZBTB27.
    He J; Wu M; Xiong L; Gong Y; Yu R; Peng W; Li L; Li L; Tian S; Wang Y; Tao Q; Xiang T
    Clin Epigenetics; 2020 Jun; 12(1):82. PubMed ID: 32517789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.